j.yeh

Breakthrough Research Published in Nature Enabled by Dynamic Single-Molecule Analysis Reveals Crucial Structure-Function Insights into DNA Repair, Resulting in New Cancer Fighting Strategies

Amsterdam, the Netherlands – July 14th, 2023 – LUMICKS, a cutting-edge life science tools company and the leading supplier of dynamic single-molecule and cell avidity analysis instruments, today announced the publication of ground-breaking cancer research in Nature. The research, enabled by LUMICKS’ C-Trap® dynamic single-molecule analysis technology, reveals new crucial…

j.yeh19 July 2023

Blog posts

m-Trap^® allows precise control of biological activities in synthetic membraneless organelles (MLOs) in real time

Until recently, the understanding of membraneless organelles (MLOs) was hindered by the inability to control their bioactivities in a precise manner. In a recent Nature Communications article from the lab of Huang and Sun, University of Hong Kong, researchers were able to overcome this obstacle by producing synthetic MLOs that…

j.yeh23 August 2022

“Avidity Enhancement” As New Strategy for Improving CAR T Therapy for AML

Press releases

Cancer Cell Paper Identifies “Avidity Enhancement” As New Strategy for Improving CAR T Therapy for Acute Myeloid Leukemia

The study details a novel strategy for better cancer treatment with CAR T cells for AML. "Avidity Enhancement", increasing cell-cell binding from both the tumor and CAR T cell side, led to a more effective eradication of tumors in mouse models of AML.

j.yeh24 May 2022

Press releases

LUMICKS Appoints Andre Nel as Chief Financial Officer

We are very pleased to attract an experienced life sciences financial executive like Andre to LUMICKS at this pivotal point in our growth. His seasoned expertise across large, global life science companies, including Illumina and Pfizer, will be invaluable to us as we accelerate our growth worldwide.

j.yeh9 May 2022

Press releases

Nature Paper Identifies “Avidity Escape” as Solid Tumor Evasion Mechanism of CAR T Cell Cancer Therapies

In this study led by the team of Dr. Marcela Maus at Harvard Medical School, the LUMICKS z-Movi® Cell Avidity Analyzer showed that loss of interferon-γ receptor (IFNγR) signaling decreased cell binding avidity between CAR T cells and their target solid tumor cells.

j.yeh2 May 2022

Press releases

LUMICKS Strengthens its Innovative C-Trap^® Solution with Launch of New Lakeview Analysis Software Platform

With the release of the Lakeview Platform, we are bridging one of the biggest hurdles in our quest to democratize dynamic single-molecule instruments: straightforward data analysis that allows scientists to translate complex data sets to biologically relevant information

j.yeh4 April 2022

Gosse Adema Professor, Radboud University Medical Centre Nijmegen

Press releases

New Study Highlights Cell Avidity’s Power to Provide Insights into the Robustness of T Cell Activation

New study by the team of Professor Gosse Adema demonstrates how cell avidity can be used to assess the effect of lead compounds on immune cells.

j.yeh22 March 2022

Press releases

Frontiers in Immunology Paper Discloses Promising New Insights into CAR-T Cell Efficacy for Cancer Therapies

Dr. Maher’s powerful research underscores the insights that our revolutionary technology can help researchers around the world discover, and help science better address core challenges in human health, particularly in designing potentially more effective immunotherapies to fight cancer.

j.yeh17 March 2022

Press releases

LUMICKS Announces 100^th Customer Placement of its C-Trap^® Product

LUMICKS has announced that it has completed installation and training for its 100th customer sale at the MRC-LMB, marking an important milestone in the company’s growth from a start-up in 2015.

j.yeh14 March 2022

Press releases

LUMICKS Unveils Groundbreaking New C-Trap^® Product at Biophysical Society Annual Meeting

New product line C-Trap ‘Edge’ adds important capabilities relevant for surface assays, which are of increasing importance in biophysical and biology research.

j.yeh18 February 2022

Join our newsletter